SEL-110

DRUG2 trials

Sponsors

Selecta Biosciences, Inc., National Cancer Institute (NCI)

Conditions

GoutMesothelioma

Phase 1

Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels

CompletedNCT02648269

Selecta Biosciences, Inc.Gout

Start: 2015-12-31End: 2016-12-31Updated: 2017-01-30

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

TerminatedNCT03436732

National Cancer Institute (NCI)Mesothelioma

Start: 2018-02-28End: 2019-04-30Updated: 2019-11-22

Related Papers

Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

Frontiers in Oncology2024-04-195 citations

Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia.

2022-01-1236 citations